EANS-News: DEWB Investment Holding NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Investment holdings

Berlin, Germany, September 3, 2009 (euro adhoc) - NOXXON Pharma AG
(NOXXON), clinical-stage developer of L-RNA based scaffolds
(Spiegelmers®) that bind their targets conceptually similar to
antibodies, announced today that the company was awarded a research
grant from Germany´s Federal Ministry of Education and Research
(BMBF) under the ministry´s small and medium enterprise innovation
initiative ("KMU-Innovativ"). The grant was presented to NOXXON
following the completion of a peer reviewed selection process. Under
the initiative NOXXON will receive 1.2 million Euro (1.7 million US$)
in funding for the impending phase I clinical development of its
candidate Spiegelmer® NOX-A12. The company develops NOX-A12 for use
in autologous hematopoietic stem cell transplantation in patients
suffering from non-Hodgkin´s lymphoma or multiple myeloma.

NOXXON´s Chief Executive Officer Frank Morich commented: "In awarding
this competitive research grant to NOXXON, the BMBF acknowledges our
tremendous progress in maturing Spiegelmer® compounds into
therapeutic candidates for human use. The transition from
pre-clinical studies to clinical trials is a critical junction in the
development of an innovative compound. We are grateful to the BMBF
for providing grant support at this crucial stage."

Spiegelmers® (L-aptamers) are chemical entities based on synthetic
mirror-image oligonucleotides. Due to their unique mirror image
configuration Spiegelmers® are not metabolized and do not hybridize
with native nucleic acids. Spiegelmers® also do not activate the
innate immune response via Toll-like receptors and have shown an
exceptionally favorable immunogenicity profile in pre-clinical
testing. The phase I clinical development of NOX-A12 will follow
closely behind that of NOXXON´s lead candidate NOX-E36, which entered
human testing in June of 2009.

About NOXXON Pharma AG: Berlin-based NOXXON Pharma AG is a
clinical-stage biotechnology company focusing on the development of
Spiegelmers® for the treatment of inflammatory diseases and
hematological indications. In addition to its in-house programs
NOXXON discovers and develops Spiegelmers® in collaboration with
partners from the pharmaceutical industry, including Eli Lilly,
Hoffmann La-Roche and Pfizer. Spiegelmers® (the German word "Spiegel"
means mirror) are chemical entities based on synthetic L-nucleic acid
scaffolds that bind their targets conceptually similar to monoclonal
antibodies. They are highly selective for their pharmacological
target and potent inhibitors of target function. The substance class
exhibits exceptional metabolic stability and an outstanding
immunogenicity profile - a new generation of improved therapeutics.
NOXXON is an investment holding of the listed venture capital company
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB),
headquartered in Jena.

Website: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225

Email: edelabre@noxxon.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade